Of these, the small molecule compound, PACMA-31, was shown to have irreversible activity against PDI (IC50 of 10μM in animal studies (35)), forming a covalent bond with active site cysteines, and exhibited in vivo activity with oral bioavailability in a mouse xenograft model of ovarian cancer (35). Here, P4HB is linked to ovarian carcinoma.